OAR 855-019-0260
Collaborative Drug Therapy Management
(1)
As used in this rule “Collaborative Drug Therapy Management” (CDTM) means the participation by a practitioner and a pharmacist in the management of drug therapy pursuant to a written agreement that includes information on the dosage, frequency, duration and route of administration of the drug, authorized by a practitioner and initiated upon a prescription order for an individual patient and:(a)
Is agreed to by one practitioner and one pharmacist; or(b)
Is agreed to by one or more practitioners in a single organized medical group, such as a hospital medical staff, clinic or group practice, including but not limited to organized medical groups using a pharmacy and therapeutics committee, and one or more pharmacists.(2)
A pharmacist shall engage in collaborative drug therapy management with a practitioner only under a written arrangement that includes:(a)
The identification, either by name or by description, of each of the participating pharmacists;(b)
The identification, by name or description, of each of the participating practitioners or group of practitioners;(c)
The name of the principal pharmacist and practitioner who are responsible for development, training, administration, and quality assurance of the arrangement;(d)
The types of decisions that the pharmacist is allowed to make, which may include:(A)
A detailed description of the types of diseases, drugs, or drug categories involved, and the activities allowed in each case;(B)
A detailed description of the methods, procedures, decision criteria, and plan the pharmacist is to follow when conducting allowed activities;(C)
A detailed description of the activities the pharmacist is to follow including documentation of decisions made and a plan or appropriate mechanism for communication, feedback, and reporting to the practitioner concerning specific decisions made. In addition to the agreement, documentation shall occur on the prescription record, patient profile, a separate log book, or in some other appropriate system;(D)
Circumstances which will cause the pharmacist to initiate communication with the practitioner, including but not limited to the need for a new prescription order and a report of a patient’s therapeutic response or any adverse effect.(e)
Training requirement for pharmacist participation and ongoing assessment of competency, if necessary;(f)
Quality assurance and periodic review by a panel of the participating pharmacists and practitioners;(g)
Authorization by the practitioner for the pharmacist to participate in collaborative drug therapy; and(h)
A requirement for the collaborative drug therapy arrangement to be reviewed and updated, or discontinued at least every two years;(3)
The collaborative drug therapy arrangement and associated records must be kept on file in the pharmacy and made available to any appropriate health licensing board upon request.(4)
Nothing in this rule shall be construed to allow therapeutic substitution outside of the CDTM agreement.
Source:
Rule 855-019-0260 — Collaborative Drug Therapy Management, https://secure.sos.state.or.us/oard/view.action?ruleNumber=855-019-0260.